Holen Sie sich die Stockscreener-App
9.06
5.67%
-0.54
Schlusskurs vom Vortag:
$9.60
Offen:
$9.52
24-Stunden-Volumen:
1.31M
Relative Volume:
0.42
Marktkapitalisierung:
$1.22B
Einnahmen:
$24.30M
Nettoeinkommen (Verlust:
$-145.57M
KGV:
-6.812
EPS:
-1.33
Netto-Cashflow:
$-149.17M
1W Leistung:
-10.16%
1M Leistung:
+15.06%
6M Leistung:
+117.68%
1J Leistung:
+182.10%
1-Tages-Spanne:
$8.88
$9.75
1-Wochen-Bereich:
$8.88
$10.22
52-Wochen-Spanne:
$1.03
$11.20
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
9.05 | 1.29B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Vivo Capital LLC Purchases Shares of 600,000 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by XTX Topco Ltd - MarketBeat
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32% - simplywall.st
Geode Capital Management LLC Grows Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
How interest rate cuts could boost Tango Therapeutics Inc. stockMarket Risk Analysis & Daily Profit Focused Screening - Newser
Stifel Initiates Coverage of Tango Therapeutics (TNGX) with Buy Recommendation - Nasdaq
Is Tango Therapeutics Inc. stock near bottom after declineJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target - Investing.com Nigeria
Stifel initiates Tango Therapeutics stock with Buy rating, $15 price target By Investing.com - Investing.com South Africa
Piper Sandler Healthcare Conference - marketscreener.com
Virtus Investment Advisers LLC Sells 38,979 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (TNGX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Can Tango Therapeutics Stock Hold Up When Markets Turn? - Trefis
Retail Trends: How interest rate cuts could boost Tango Therapeutics Inc stockRecession Risk & Fast Exit Strategy with Risk Control - BỘ NỘI VỤ
Tango Therapeutics Inc trading resumes - MSN
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy - MSN
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Tango Therapeutics launches $100M at-the-market stock offering - MSN
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - MSN
Tango Therapeutics (NASDAQ:TNGX) Hits New 52-Week HighTime to Buy? - MarketBeat
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Tango Therapeutics stock hits 52-week high at 9.7 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal TestingBuy (TNGX) - Seeking Alpha
Tango Therapeutics stock hits 52-week high at 9.7 USD - Investing.com India
Tango Therapeutics launches new $100 million at-the-market stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc files for mixed shelf offeringSEC filing - marketscreener.com
Tango Therapeutics files prospectus for resale of 1.7 million shares by selling stockholderSEC filing - marketscreener.com
Tango Therapeutics launches new $100 million at-the-market stock offering - Investing.com Nigeria
Tango Therapeutics Enters New Sales Agreement with Leerink - TipRanks
[S-3] Tango Therapeutics, Inc. Shelf Registration Statement | TNGX SEC FilingForm S-3 - Stock Titan
[8-K] Tango Therapeutics, Inc. Reports Material Event | TNGX SEC FilingForm 8-K - Stock Titan
Why Tango Therapeutics Inc. stock remains on watchlists2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Short interest data insights for Tango Therapeutics Inc.Weekly Trade Review & Accurate Intraday Trade Tips - newser.com
How analysts rate Tango Therapeutics Inc. stock todayWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
TNGX: Pivotal pancreatic cancer study advances, with strong combo data and cash runway into 2028 - TradingView
Will Tango Therapeutics Inc. stock benefit from automationForecast Cut & Short-Term Trading Alerts - newser.com
TNGX: Vopimetostat advances in pivotal and combo studies, with strong efficacy and cash runway into 2028 - TradingView
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):